Yılmaz Kıroğlu

Pamukkale University, Denisli, Denizli, Turkey

Are you Yılmaz Kıroğlu?

Claim your profile

Publications (6)8.35 Total impact

  • Mustafa Çam · Eylem Degirmenci · Yılmaz Kıroğlu · Attila Oğuzhanoğlu ·

    11/2015; 3(1). DOI:10.18035/emj.v3i1.271
  • Gonca Ayşe Ünal · Ayşe Nur İnci Kenar · Hasan Herken · Yılmaz Kıroğlu ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The effects of methylphenidate (MPH) treatment on N-acetyl aspartate (NAA), Choline and Creatine are being examined in individuals with different subtypes of attention deficit hyperactivity disorder (ADHD). Sixty ADHD subjects were included into the study aging between 18 and 60 years. Levels of NAA, creatine and choline in anterior cingulate cortex, cerebellum, striatum and dorsolateral prefrontal cortex were measured with magnetic resonance spectroscopy. Then, 10mg oral MPH was given to the subjects and the same metabolite levels were measured after an interval of 30minutes. Distribution of the patients according to the ADHD subtypes was as follows: 21 of them (35,0%) were in the inattentive type, 11 of them (18,3%) were in the hyperactive type and 28 of them were (46,7%) in the combined type. Changes of brain metabolite levels after MPH were found not to be statistically significantly different between the subtypes. The increase of choline levels after MPH compared to the levels of choline before MPH in striatum in the combined type patients were statistically significant. No clear association was found between ADHD subtypes and changes of brain metabolites with use of MPH in adult ADHD. Copyright © 2015. Published by Elsevier Ireland Ltd.
    Neuroscience Letters 08/2015; 604. DOI:10.1016/j.neulet.2015.08.006 · 2.03 Impact Factor
  • Eylem Degirmenci · Taner Degirmenci · Ebru Nevin Cetin · Yılmaz Kıroğlu ·

    Acta neurologica Belgica 06/2014; 115(2). DOI:10.1007/s13760-014-0314-y · 0.89 Impact Factor

  • 09/2013; 19(3):116-116. DOI:10.4274/Tnd.88598
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Previous studies have determined the neurochemical metabolite abnormalities in major depressive disorder (MDD). The results of studies are inconsistent. Severity of depression may relate to neurochemical metabolic changes. The aim of this study is to investigate neurochemical metabolite levels in the prefrontal cortex (PFC) of patients with mild/moderate MDD. Twenty-one patients with mild MDD, 18 patients with moderate MDD, and 16 matched control subjects participated in the study. Patients had had their first episode. They had not taken treatment. The severity of depression was assessed by the Hamilton Rating Scale for Depression (HAM-D). Levels of N-acetyl aspartate (NAA), choline-containing compounds (Cho), and creatine-containing compounds (Cr) were measured using proton magnetic resonance spectroscopy (1H-MRS) at 1.5 T, with an 8-cm(3) single voxel placed in the right PFC. The moderate MDD patients had lower NAA/Cr levels than the control group. No differences were found in neurochemical metabolite levels between the mild MDD and control groups. No correlation was found between the patients' neurochemical metabolite levels and HAM-D scores. Our findings suggest that NAA/Cr levels are low in moderate-level MDD in the PFC. Neurochemical metabolite levels did not change in mild depressive disorder. Our results suggest that the severity of depression may affect neuronal function and viability. Studies are needed to confirm this finding, including studies on severely depressive patients.
    Neuropsychiatric Disease and Treatment 08/2013; 9:1053-9. DOI:10.2147/NDT.S42627 · 1.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to compare schizoaffective disorder, bipolar disorder and schizophrenia based on (1)H-MRS metabolite values in dorsolateral prefrontal cortex and executive functions. The subjects comprised 15 patients with bipolar disorder type I (BD), 15 with schizophrenia (SCH), 15 with schizoaffective disorder (SAD) and 15 healthy controls. We performed proton magnetic resonance spectroscopy ((1)H-MRS) of the dorsolateral prefrontal cortex (DLPFC) bilaterally. Levels of N-acetyl aspartate (NAA), choline-containing compounds (Cho) and creatine-containing compounds (Cr) were measured in the DLPFC using (1)H-MRS. We administered the Wisconsin Card Sorting Test (WCST) and the Stroop Test (ST) to evaluate executive functions. The SAD, BD and SCH patients had lower levels of NAA than the control group. The SAD and BD patients had low levels of Cho compared to the control group. The left DLPFC Cr levels in all of the patient groups and the right DLPFC Cr levels in the BD and SAD groups were lower than in the control group. The levels of NAA Cho and Cr were not related to executive functions and attention performance. Cr level were related to attention processes, only in SCH. Our results indicate that NAA levels are reduced in schizoaffective disorder, bipolar disorder and schizophrenia, but the reduction in the levels of NAA is not a distinctive feature among these three illnesses. Schizoaffective and bipolar disorders have similar features related to the levels of compounds containing Cho and Cr. This similarity may be related to these illnesses both having an affective basis.
    Progress in Neuro-Psychopharmacology and Biological Psychiatry 04/2012; 37(1):176-81. DOI:10.1016/j.pnpbp.2012.01.010 · 3.69 Impact Factor